A pilot study has provided evidence that the hydrophilic bile acid TUDCA is safe and possibly effective for the treatment of amyotrophic lateral sclerosis (ALS). 34 patients with ALS were randomly assigned to TUDCA or placebo as add-on therapy to riluzole. TUDCA was well tolerated, and the patients who received the drug showed significantly reduced disease progression over the 54-week treatment period compared with the placebo group.
References
Elia, A. E. et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 10.1111/ene.12664
Rights and permissions
About this article
Cite this article
TUDCA shows early promise for the treatment of amyotrophic lateral sclerosis. Nat Rev Neurol 11, 125 (2015). https://doi.org/10.1038/nrneurol.2015.21
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.21